Search
Filter Results
Displaying 51–60 of 852 results for “vision connection”
-
Jul 1, 2016
Research NewsAt VISIONS 2016, FFB’s national conference, the Foundation honored him with its Ed Gollob Board of Directors Award for breakthrough research conducted within the past year.
-
Nov 2, 2023
New Report: Vitamin A Supplementation Provides No Vision Benefit to RP Patients
Research NewsThe report also concludes that vitamin E supplementation accelerates vision loss for RP patients
-
Apr 21, 2023
Research NewsClinical trial participants with advanced vision loss from RP were able to identify fruits and vegetables
-
Mar 2, 2023
Foundation NewsThe May 11th gala will raise awareness and fund research leading to treatments and cures for blinding retinal diseases.
-
Dec 15, 2021
Foundation NewsProgram to have special translational research emphasis on inherited macular dystrophy.
-
June 17–June 18, 2022. Disney’s Coronado Springs Resort, Orlando, FL. VISIONS 2022, the national conference of the Foundation Fighting Blindness, is a one-of-a-kind event in which individuals who are visually impaired, and their families, hear about exciting advancements in blindness research.
-
Jan 14, 2014
Vision Improvements Reported in Choroideremia Gene Therapy Clinical Trial
Foundation NewsFive of six participants in the initial study group have sustained vision improvements in their treated eyes in dim settings.
-
Jul 9, 2013
Foundation NewsWilliam W. Hauswirth, Ph.D., Honored for Lifetime Scientific Achievement at VISIONS 2013
-
Jan 15, 2013
Why Face Recognition Can Be Difficult with Central Vision Loss
Research NewsDiseases such as age-related macular degeneration, cone-rod dystrophy and Stargardt disease cause scotomas, or blind spots, which often have devastating effects on central vision. They cause gaps in a person’s visual field, making it difficult to see words in a book, images on a computer monitor or TV and the features of someone’s face.
-
May 19, 2022
ProQR’s Sepofarsen Improves Vision Significantly for Girl with LCA10
Research NewsHowever, the Phase 2/3 Illuminate trial for sepofarsen didn’t meet its endpoints at 12 months